ESMO: Roche's Tecentriq-Cotellic duo tried—and failed—to beat Merck's Keytruda in melanoma

28th September 2019 Uncategorised 0

It was a decent idea: Team Tecentriq, the Roche checkpoint inhibitor, with its Exelixis-partnered MEK inhibitor Cotellic to treat melanoma. Unfortunately, the idea didn’t work out as planned—at least not when it came to beating the foe it chose to challenge, Merck & Co.’s megablockbuster PD-1 immunotherapy Keytruda

More: ESMO: Roche's Tecentriq-Cotellic duo tried—and failed—to beat Merck's Keytruda in melanoma
Source: fierce